[go: up one dir, main page]

WO2002029032A3 - Manipulation de cellule entiere par mutagenese d'une partie substantielle d'un genome de depart, par combinaison de mutations et eventuellement par repetition - Google Patents

Manipulation de cellule entiere par mutagenese d'une partie substantielle d'un genome de depart, par combinaison de mutations et eventuellement par repetition Download PDF

Info

Publication number
WO2002029032A3
WO2002029032A3 PCT/US2001/031004 US0131004W WO0229032A3 WO 2002029032 A3 WO2002029032 A3 WO 2002029032A3 US 0131004 W US0131004 W US 0131004W WO 0229032 A3 WO0229032 A3 WO 0229032A3
Authority
WO
WIPO (PCT)
Prior art keywords
provides
novel
methods
gene
mutagenizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/031004
Other languages
English (en)
Other versions
WO2002029032A2 (fr
Inventor
Jay M Short
Pengcheng Fu
Martin Latterich
Jing Wei
Michael Levin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Enzymes LLC
Original Assignee
Diversa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/677,584 external-priority patent/US7033781B1/en
Priority claimed from PCT/US2001/019367 external-priority patent/WO2001096551A2/fr
Priority to AU2002211402A priority Critical patent/AU2002211402A1/en
Priority to CA002424178A priority patent/CA2424178A1/fr
Priority to JP2002532602A priority patent/JP2004536553A/ja
Priority to EP01979431A priority patent/EP1415160A2/fr
Application filed by Diversa Corp filed Critical Diversa Corp
Priority to IL15515401A priority patent/IL155154A0/xx
Priority to US10/398,271 priority patent/US20050124010A1/en
Priority to DE01979431T priority patent/DE01979431T1/de
Publication of WO2002029032A2 publication Critical patent/WO2002029032A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002029032A3 publication Critical patent/WO2002029032A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Ecology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés de transformation cellulaire, d'évolution dirigée et de criblage utiles pour produire de nouveaux organismes transgéniques possédant des propriétés voulues. Dans une forme de réalisation, l'invention concerne un procédé de production d'organisme transgénique, tel qu'un microbe ou une plante, comportant une pluralité de caractéristiques activables de manière différenciée. L'invention concerne aussi un procédé de remaniement de gènes et de voies géniques par l'introduction de séquences régulatrices, tels des promoteurs, qui peuvent être activées chez un hôte voulu et sont ainsi capables de conférer une capacité d'activation à une nouvelle voie génique après introduction de celle-ci dans un hôte voulu; par exemple, une nouvelle voie génique artificielle, produite sur la base de modèles de progéniteurs dérivés de microbes, qui peut être activée dans une cellule végétale. Cette invention concerne aussi un procédé de production de nouveaux organismes hôtes possédant une expression accrue de caractéristiques voulues, de gènes recombinés et de produits géniques; de nouveaux procédés servant à déterminer des profils de polypeptides et des variations d'expression de protéines, ces procédés pouvant être appliqués à tous les types d'échantillons décrits; des procédés permettant d'identifier et de quantifier simultanément des protéines individuelles dans des mélanges complexes de protéines. De plus, l'invention concerne des procédés de mise au point cellulaire et métabolique de nouveaux phénotypes modifiés utilisant une analyse de flux métabolique « en ligne » ou « en temps réel ».
PCT/US2001/031004 2000-09-30 2001-10-01 Manipulation de cellule entiere par mutagenese d'une partie substantielle d'un genome de depart, par combinaison de mutations et eventuellement par repetition Ceased WO2002029032A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE01979431T DE01979431T1 (de) 2000-09-30 2001-10-01 Konstruktion ganzer zellen durch mutagenese eines wesentlichen anteils eines ausgangsgenoms, kombination von mutationen und gegebenfalls wiederholung
US10/398,271 US20050124010A1 (en) 2000-09-30 2001-10-01 Whole cell engineering by mutagenizing a substantial portion of a starting genome combining mutations and optionally repeating
CA002424178A CA2424178A1 (fr) 2000-09-30 2001-10-01 Manipulation de cellule entiere par mutagenese d'une partie substantielle d'un genome de depart, par combinaison de mutations et eventuellement par repetition
JP2002532602A JP2004536553A (ja) 2000-09-30 2001-10-01 始原ゲノムの本質部分突然変異、突然変異の組合せおよび任意反復による全細胞工学
EP01979431A EP1415160A2 (fr) 2000-09-30 2001-10-01 Manipulation de cellule entiere par mutagenese d'une partie substantielle d'un genome de depart, par combinaison de mutations et eventuellement par repetition
AU2002211402A AU2002211402A1 (en) 2000-09-30 2001-10-01 Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
IL15515401A IL155154A0 (en) 2000-09-30 2001-10-01 Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/677,584 US7033781B1 (en) 1999-09-29 2000-09-30 Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
US09/677,584 2000-09-30
US27970201P 2001-03-28 2001-03-28
US60/279,702 2001-03-28
US11936701A 2001-06-14 2001-06-14
PCT/US2001/019367 WO2001096551A2 (fr) 2000-06-14 2001-06-14 Ingenierie cellulaire complete par mutagenese d'une partie substantielle d'un genome de depart, par combinaison de mutations et eventuellement repetition
USPCT/US01/19367 2001-06-14

Publications (2)

Publication Number Publication Date
WO2002029032A2 WO2002029032A2 (fr) 2002-04-11
WO2002029032A3 true WO2002029032A3 (fr) 2004-03-04

Family

ID=27382299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/031004 Ceased WO2002029032A2 (fr) 2000-09-30 2001-10-01 Manipulation de cellule entiere par mutagenese d'une partie substantielle d'un genome de depart, par combinaison de mutations et eventuellement par repetition

Country Status (1)

Country Link
WO (1) WO2002029032A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US7262012B2 (en) 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044864A1 (en) * 2001-07-20 2003-03-06 Diversa Corporation Cellular engineering, protein expression profiling, differential labeling of peptides, and novel reagents therefor
AU2004254640B2 (en) 2003-07-02 2010-08-26 Bp Corporation North America Inc. Glucanases, nucleic acids encoding them and methods for making and using them
WO2005021714A2 (fr) 2003-08-11 2005-03-10 Diversa Corporation Laccases, acides nucleiques codant pour ces enzymes et procedes permettant de les produire et de les utiliser
CN101432292B (zh) 2004-06-16 2013-03-13 维莱尼姆公司 对叶绿素进行酶促脱色的组合物和方法
US20080070291A1 (en) 2004-06-16 2008-03-20 David Lam Compositions and Methods for Enzymatic Decolorization of Chlorophyll
EP2886658A1 (fr) 2005-03-10 2015-06-24 BASF Enzymes LLC Enzymes de lyase, acides nucléiques les codant et leurs procédés de fabrication et d'utilisation
JP5343212B2 (ja) 2005-03-15 2013-11-13 ヴェレニウム コーポレイション セルラーゼ、それらをコードする核酸、並びにそれらを作製及び使用する方法
US20070004041A1 (en) * 2005-06-30 2007-01-04 Codon Devices, Inc. Heirarchical assembly methods for genome engineering
MY160770A (en) 2006-02-10 2017-03-15 Verenium Corp Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
PL1989302T3 (pl) 2006-02-14 2019-03-29 Bp Corp North America Inc Ksylanazy, kodujące je kwasy nukleinowe i sposoby ich wytwarzania i stosowania
US8043837B2 (en) 2006-03-07 2011-10-25 Cargill, Incorporated Aldolases, nucleic acids encoding them and methods for making and using them
US8546118B2 (en) 2006-03-07 2013-10-01 Verenium Corporation Aldolases, nucleic acids encoding them and methods for making and using them
EP2013620A2 (fr) * 2006-04-17 2009-01-14 Morphotek, Inc. Technologie d'evolution du genome entier appliquee a l'amelioration des rendements de proteine et d'anticorps par les cellules
WO2009020459A2 (fr) 2006-08-04 2009-02-12 Verenium Corporation Glucanases, acides nucléiques codant ceux-ci et procédés pour les fabriquer et les utiliser
JP2010516296A (ja) 2007-01-30 2010-05-20 ヴェレニウム コーポレイション リグノセルロース性物質を処理する酵素、前記をコードする核酸並びに前記を製造及び使用する方法
DK2708602T3 (da) 2007-10-03 2019-06-03 Bp Corp North America Inc Xylanaser, nukleinsyrer der koder for dem og fremgangsmåder til fremstilling og anvendelse af dem
US8709772B2 (en) 2008-01-03 2014-04-29 Verenium Corporation Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them
GB201314695D0 (en) * 2013-08-16 2013-10-02 Oxford Nanopore Tech Ltd Method
BR112018011503A2 (pt) 2015-12-07 2018-12-04 Zymergen Inc promotores da corynebacterium glutamicum
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
EP4386087A3 (fr) * 2016-06-15 2024-08-14 President and Fellows of Harvard College Procédés de conception génomique basée sur des règles
KR102345899B1 (ko) 2016-06-30 2021-12-31 지머젠 인코포레이티드 박테리아 헤모글로빈 라이브러리를 생성하는 방법 및 이의 용도
US10544411B2 (en) 2016-06-30 2020-01-28 Zymergen Inc. Methods for generating a glucose permease library and uses thereof
EP3635111A1 (fr) * 2017-06-06 2020-04-15 Zymergen, Inc. Mutagenèse de transposon à haut débit
EP3878961A1 (fr) * 2017-06-06 2021-09-15 Zymergen, Inc. Plate-forme d'ingénierie génomique htp permettant d'améliorer escherichia coli
CN110914912A (zh) * 2017-06-06 2020-03-24 齐默尔根公司 对基因修饰进行优先级排序以增加表型优化的吞吐量
CN110914425B (zh) * 2017-06-06 2024-06-25 齐默尔根公司 用于改良刺糖多孢菌的高通量(htp)基因组工程改造平台
US20210254047A1 (en) * 2018-09-04 2021-08-19 Encodia, Inc. Proximity interaction analysis
EP3696278A1 (fr) * 2019-02-13 2020-08-19 Nipd Genetics Public Company Limited Procédé de détermination de l'origine d'acides nucléiques dans un échantillon mixte
WO2020184080A1 (fr) * 2019-03-13 2020-09-17 パナソニックＩｐマネジメント株式会社 Procédé de fourniture d'informations, programme de fourniture d'informations, dispositif de fourniture d'informations, dispositif de diffusion de parfum, et dispositif de gestion d'informations
US20220243195A1 (en) * 2019-06-21 2022-08-04 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
CN114774398B (zh) * 2022-06-20 2022-10-04 北京惠之衡生物科技有限公司 一种重组ek酶工程菌的高密度发酵方法
WO2025010715A1 (fr) * 2023-07-13 2025-01-16 深圳华大生命科学研究院 Système et procédé de confinement biologique modifié
WO2025239464A1 (fr) * 2024-05-14 2025-11-20 대한뉴팜(주) Nouveau peptide et son utilisation antivirale

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011208A1 (fr) * 1998-08-25 2000-03-02 University Of Washington Analyse quantitative rapide de proteines ou de fonction proteique dans des melanges complexes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011208A1 (fr) * 1998-08-25 2000-03-02 University Of Washington Analyse quantitative rapide de proteines ou de fonction proteique dans des melanges complexes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GYGI S P ET AL: "QUANTITATIVE ANALYSIS OF COMPLEX PROTEIN MIXTURES USING ISOTOPE-CODED AFFINITY TAGS", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 17, no. 10, October 1999 (1999-10-01), pages 994 - 999, XP001010578, ISSN: 1087-0156 *
JI J ET AL: "Strategy for qualitative and quantitative analysis in proteomics based on signature peptides", JOURNAL OF CHROMATOGRAPHY. BIOMEDICAL APPLICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 745, no. 1, 4 August 2000 (2000-08-04), pages 197 - 210, XP004215299, ISSN: 0378-4347 *
ODA Y ET AL: "ACCURATE QUANTITATION OF PROTEIN EXPRESSION AND SITE-SPECIFIC PHOSPHORYLATION", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 12, June 1999 (1999-06-01), pages 6591 - 6596, XP001080471, ISSN: 0027-8424 *
SHEVCHENKO A ET AL: "Rapid 'de Novo' Peptide Sequencing by a Combination of Nanoelectrospray, Isotopic Labeling and a Quadrupole/Time-of-Flight Mass Spectrometer", RAPID COMMUNICATIONS IN MASS SPECTROMETRY, HEYDEN, LONDON, GB, vol. 11, 1997, pages 1015 - 1024, XP002101143, ISSN: 0951-4198 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US7282334B2 (en) 2000-12-12 2007-10-16 Alligator Bioscience, Ab Method for in vitro molecular evolution of protein function
US7563578B2 (en) 2000-12-12 2009-07-21 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US7262012B2 (en) 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations

Also Published As

Publication number Publication date
WO2002029032A2 (fr) 2002-04-11

Similar Documents

Publication Publication Date Title
WO2002029032A3 (fr) Manipulation de cellule entiere par mutagenese d'une partie substantielle d'un genome de depart, par combinaison de mutations et eventuellement par repetition
Myers et al. A general method for saturation mutagenesis of cloned DNA fragments
Haracska et al. Physical and functional interactions of human DNA polymerase η with PCNA
Wentzel et al. Sequence requirements of the GPNG β-turn of the Ecballium elaterium trypsin inhibitor II explored by combinatorial library screening
Hsiao et al. Molecular paleontology: a biochemical model of the ancestral ribosome
DE69921982D1 (de) Neuartiges verfahren zur identifizierung von klonen mit einer gewünschten biologischen eigenschaft, ausgehend von einer expressionsgenbank
SG135053A1 (en) Generation and selection of protein library in silico
DE60323067D1 (de) Verfahren zur erzeugung doppelsträngiger dna mit einem 3'-einzelstranganteil und verwendungen dieser komplexe zur rekombination
DE69824597D1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
JP2005520244A5 (fr)
WO2003031928A3 (fr) Genie cellulaire, profilage d'expression de proteines, marquage differentiel de peptides, et nouveaux reactifs associes
ATE374247T1 (de) Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
WO2001096551A3 (fr) Ingenierie cellulaire complete par mutagenese d'une partie substantielle d'un genome de depart, par combinaison de mutations et eventuellement repetition
ATE377074T1 (de) Methode zur bereitstellung von dna sequenzen
DE602004013361D1 (en) Amp
ATE298004T1 (de) Diagnostische sequenzierung durch eine kombination von spezifischer spaltung und massenspektrometrie
EP1272669A4 (fr) Criblage a debit eleve de bibliotheques d'adn exprimees dans des champignons filamenteux
DE69902924D1 (de) Neue methoden zum auffinden von liganden- und ziel-biomolekülen
Wan et al. A site-directed mutagenesis method particularly useful for creating otherwise difficult-to-make mutants and alanine scanning
Hellman et al. A rapidly evolving region in the immunoglobulin heavy chain loci of rat and mouse: postulated role of (dC-dA) n·(dG-dT) n sequences
Palm-Forster et al. A mutagenesis-based screen to rapidly identify phosphorylation sites in mitogen-activated protein kinase substrates
JP2007526221A (ja) 系統発生的に関連のある配列のライブラリー
Gaastra et al. The amino‐acid sequence of kangaroo pancreatic ribonuclease
WO2002004630A3 (fr) Procédés de synthèse recombinatoire d"acides nucléiques
Yang et al. Construction and analysis of high-complexity ribosome display random peptide libraries

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2424178

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 155154

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002532602

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002211402

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001979431

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10398271

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001979431

Country of ref document: EP